Related Experiment Videos
Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Dimitrios Makrygiannakis1, Erik af Klint, Sergiu-Bogdan Catrina
1Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
Arthritis and Rheumatism
|April 29, 2006
Summary
Intraarticular corticosteroids reduce synovial RANKL and OPG, decreasing bone destruction markers in inflammatory arthritis. This explains their benefit in preventing joint erosion.
Area of Science:
- Rheumatology and Immunology
- Bone Biology
- Pharmacology
Background:
- Intraarticular corticosteroids are common for inflammatory arthritis.
- Their impact on bone-regulating molecules is not well understood.
Purpose of the Study:
- To investigate corticosteroid effects on synovial RANKL and OPG expression.
- To explore the role of these molecules in corticosteroid-mediated joint protection.
Main Methods:
- Immunohistochemistry on synovial biopsies from 13 arthritis patients before and after corticosteroid injection.
- Flow cytometry for dexamethasone (DEX) effects on rheumatoid arthritis synovial fluid lymphocytes.
- In vitro Western blotting for DEX effects on osteoblast-like cells.
Main Results:
- Corticosteroids decreased synovial T cells and RANKL expression, lowering the RANKL:OPG ratio.
- DEX reduced RANKL on lymphocytes and in osteoblast-like cells, especially with TNF stimulation.
- Macrophage counts (CD68+, CD163+) remained unchanged.
Conclusions:
- Corticosteroid-induced inflammation reduction is linked to down-modulated bone destruction markers.
- These findings support the use of corticosteroids for mitigating joint erosion in arthritis.